Evaluation of risk factors associated with carboplatin and nab-paclitaxel treatment suspension in patients with non-small cell lung cancer.

Yoshitaka SaitoYoh TakekumaNaofumi ShinagawaMitsuru Sugawara

Published in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2022)

We observed that liver dysfunction at baseline is a risk factor for treatment suspension. In addition, age ≥65 years and PS 2 can result in treatment suspension owing to neutropenia and/or infection during CBDCA + nab-PTX treatment.

Keyphrases

randomized controlled trial
clinical trial
squamous cell carcinoma
combination therapy
tyrosine kinase
advanced non small cell lung cancer
replacement therapy
open label
phase ii study
rectal cancer
double blind